2014 NEI
PSYCHOPHARMACOLOGY
CONGRESS

NOVEMBER 13 - 16, 2014
COLORADO SPRINGS, CO

Where every session is a keynote presentation!

Experience four days of interactive presentations with real-life applications.

Exceptional education for superior patient care

Inspiring content from elite speakers

The latest treatment strategies

Social networking opportunities

Call us at 1-888-535-5600 or visit www.neiglobal.com today!
BRAINSTORMS
Clozapine: Is Now the Time for More Clinicians to Adopt This Orphan?
Stephen M. Stahl 279

REVIEW ARTICLES
Quality of life before and after cosmetic surgery
Jean-Charles Bensoussan, Michael A. Bolton, Sarah Pi, Allycin L. Powell-Hicks, Anna Postolova, Bahram Razani, Kevin Reyes and Waguih William IsHak 282

Metabolic syndrome and major depression
Donatella Marazziti, Grazia Rutigliano, Stefano Baroni, Paola Landi and Liliana Dell’Osso 293

Risks of neurobehavioral teratogenicity associated with prenatal exposure to valproate monotherapy: a systematic review with regulatory repercussions
Salvatore Gentile 305

ORIGINAL RESEARCH
Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study
Margarita A. Morozova, Taisiya A. Lepilkina, Georgy E. Rupchev, Allan G. Beniaishvili, Denis S. Burminsky, Sergey S. Potanin, Evgeny V. Bondarenko, Vasily I. Kazey, Yan Lavrovsky and Alexandre V. Ivachtchenko 316

Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials
Chi-Un Pae, Ashvin A. Patkar, Saheen Jang, Kimberly B. Portland, Sungwon Jung and J. Craig Nelson 324

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
Leslie Citrome, Peter J. Weiden, Joseph P. McEvoy, Christoph U. Correll, Josephine Cucchiaro, Jay Hsu and Antony Loebel 330

Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics
Giacomo Grassi, Lorenzo Poli, Andrea Cantisani, Lorenzo Righi, Gabriella Ferrari and Stefano Pallanti 340

Augmentative transcranial direct current stimulation (tDCS) in poor responder depressed patients: a follow-up study
Bernardo Dell’Osso, Cristina Dobrea, Chiara Arici, Beatrice Benatti, Roberta Ferrucci, Maurizio Vergari, Alberto Priori and A. Carlo Altamura 347

CORRIGENDUM
The impact of periventricular white matter lesions in patients with bipolar disorder type I – CORRIGENDUM
Gianluca Serafini, Maurizio Pompili, Marco Innamorati, Nicoletta Girardi, Leonardo Strusi, Mario Amore, Leo Sher, Xiaoda Gonda, Zoltan Rihmer and Paolo Girardi 355
Editor-in-Chief
Stephen M. Stahl, Adjunct Professor of Psychiatry at the University of California San Diego, USA; Honorary Visiting Senior Fellow at the University of Cambridge, UK.

Field Editors
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai, USA
Terence Arthur Ketter, Stanford University, USA
Thomas E. Schlaepfer, University Hospital Bonn, Germany
Carlos A. Zarate, National Institute of Mental Health, USA

Deputy Editor
Thomas L. Schwartz, SUNY Upstate Medical University at Syracuse, USA

Editorial Board
Maria Conceição do Rosario, University of São Paulo Medical School, Brazil
Jeffrey L. Cummings, Cleveland Clinic, USA
Thilo Deckerbach, Harvard Medical School, USA
Koen Demyttenaere, University Psychiatric Center KuLeuven, Belgium
Karen D. Ersche, University of Cambridge, UK
Robert L. Findling, The Johns Hopkins Hospital, USA
Mark S. George, Medical University of South Carolina, USA
Ira D. Glick, Stanford University, USA
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai, USA
Eric Hollander, Albert Einstein College of Medicine and Montefiore Medical Center, USA
Daphne Holt, Harvard Medical School, USA
Peter B. Jones, University of Cambridge, UK
Andres M. Kanner, University of Miami, USA
Terence Arthur Ketter, Stanford University, USA
Antony D. Loebe, New York University School of Medicine, USA
Donatella Marazziti, University of Pisa, Italy
Herbert Y. Meltzer, Northwestern University, USA
Philip Mitchell, University of New South Wales, Australia
Jun Nakamura, University of Occupational and Environmental Health, Japan
Humberto Nicolini, National Institutes of Health, Minister of Health, México
Andrew A. Nierenberg, Harvard Medical School, USA
Stefano Pallanti, University of Florence, Italy
Katharine A. Phillips, Brown University, USA
Diego A. Pizzagalli, Harvard Medical School, USA
Mark H. Pollack, Rush University Medical Center, USA
Mark H. Rapoport, Emory University, USA
Irismar Reis de Oliveira, Universidade Federal da Bahia, Brazil
Trevor W. Robbins, University of Cambridge, UK
Peter P. Roy-Byrne, University of Washington School of Medicine, USA
Barbara J. Sahakian, University of Cambridge, UK
Gerard Sanacora, Yale University School of Medicine, USA
Alan F. Schatzberg, Stanford University School of Medicine, USA
Thomas L. Schwartz, SUNY Upstate Medical University in Syracuse, USA
Jordan W. Smoller, Harvard Medical School, USA
Dan J. Stein, University of Cape Town (UCT), South Africa
Stephen Strakowski, University of Cincinnati, USA
T. Scott Stroup, Columbia University, USA
Frank I. Tarazi, Harvard Medical School, USA
Michael E. Thase, University of Pennsylvania, USA
Michael Trimble, National Hospital for Neurology, Queen Square, London
Madhukar H. Trivedi, University of Texas Southwestern Medical Center, USA
Karen Dineen Wagner, The University of Texas Medical Branch, USA
Katherine D. Warburton, California Department of State Hospitals, USA
Stephen R. Wisniewski, University of Pittsburgh, USA
Shigeto Yamawaki, Hiroshima University, Japan
Carlos A. Zarate, Jr., National Institute of Mental Health, USA
Joseph Zohar, Tel Aviv University, Israel

Content Editor
Lisa Arrington, Cambridge University Press (larrington@cambridge.org)

Cover Image: The image on the cover shows a hypothetical model whereby glutamate is released from an intracortical pyramidal neuron and binds to an NMDA receptor on a GABA-ergic interneuron. GABA is then released and binds to receptors on the axon of another glutamate pyramidal neuron. This inhibits the neuron, thus reducing the release of cortical glutamate. The GABA interneuron and its NMDA synapse from the first neuron to the second is the hypothetical site of glutamate dysfunction in schizophrenia.

Copyright © 2014 Stephen M. Stahl. Reproduced with permission.
Aims and Scope

CNS Spectrums aims to be the premiere journal covering all aspects of clinical neurosciences, neurotherapeutics and neuropsychopharmacology. From 2012 the journal will primarily focus on the publication of authoritative, cross-disciplinary review and opinion material publishing advances and controversial issues with pertinence to the clinician. In particular we aim to publish reviews and articles in translational neuroscience, biological psychiatry and neuropsychopharmacology that explain clinically relevant neuroscience discoveries in a way that makes these findings accessible and understandable to clinicians and clinical investigators. We will emphasize new therapeutics of all types in clinical neurosciences, mental health, psychiatry, and neurology, especially first in man studies and proof of concept studies. Our focus will be not just drugs, but novel psychotherapies and neurostimulation therapeutics as well. CNS Spectrums will in addition, continue to publish original research and commentaries that focus on emergent areas of research. Subject coverage shall span the full spectrum of neuropsychiatry focusing on translational issues and those crossing traditional boundaries between neurology and psychiatry.

Submitting Manuscripts to CNS Spectrums

All submissions to CNS Spectrums should be prepared in accordance with the instructions for authors and in the style of the Journal. Manuscripts should be submitted through the dedicated CNS Spectrums ScholarOne Manuscripts website: http://mc.manuscriptcentral.com/cnsspectr

CNS Spectrums will consider and encourage the following types of articles for publication: Review Article—Comprehensive article summarizing and synthesizing the literature on various topics presented in a scholarly and clinically relevant fashion; Original Research—Reports the results of a clinical study and contains original research; Opinion—Address a current topic of high interest, which has substantial evidence but has not yet been established; Commentary—An article that is written in reaction to previously published articles; usually encouraging a level of debate; the journal will also include Brainstorms and Editorials that shall be commissioned or written by the Editor in Chief.

Instructions for Contributors

The Instructions for Contributors are available on the Cambridge Journals Online web site at: http://journals.cambridge.org/CNSifc

Indexing

CNS Spectrums is indexed by Index Medicus/MEDLINE and Web of Science (Thomson Reuters) as well as appearing in the annual Journal Citation Report. Introduced in 1996, the journal was acquired in whole by Cambridge University Press in November of 2011.

Subscriptions


© Cambridge University Press 2014. All rights reserved.

No part of this publication may be reproduced, in any form or by any means, electronic, photocopying, or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: http://www.cambridge.org/rights/permissions/permission.htm. Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center http://www.copyright.com, email: info@copyright.com.

Rights & permissions requests can be applied for online within each article by clicking “Request Permissions” within the table of contents or in the fulltext version of a specific article. Requests will be processed via the CCC Rightslink system and processed immediately.

CNS Spectrums (ISSN: Print 1092-8529; eISSN: 2165-6509) is published bimonthly by Cambridge University Press.

Postmaster

Send address changes in the U.S.A., Canada, and Mexico to CNS Spectrums, Cambridge University Press, Journals Dept., 100 Brook Hill Drive, West Nyack, NY 10994-2133, U.S.A. Send address changes elsewhere to CNS Spectrums, Cambridge University Press, The Edinburgh Building, Shaftesbury Road, Cambridge CB2 8RU, England.

Online availability

CNS Spectrums is hosted on the Cambridge Journals Online (CJO) service at http://journals.cambridge.org/cns

Institutional subscribers: Access to full-text articles online is only granted to subscription options offering an online component. Subscriptions must be activated by the purchasing institution using the instructions provided at the time of purchase; see information for subscribers at: http://journals.cambridge.org/

Reprint and Advertising Sales

Inquiries for bulk reprint sales and placement of advertising should be sent to the Journals Sales Department of Cambridge University Press: USAdSales@cambridge.org